VARIOUS TREATMENT PATTERN & MEDICAL PROCEDURES TO TREAT AND PREVENT MONKEY POX IN HUMAN

SHREYA SINGH[1], MEGHNA MISRA[2], PREETI[3], SHIPRA SINGH[4], KRISHNA JEE[5]

1. ss.drxshreyasingh@gmail.com[1], 2. meghnamisra40@gmail.com[2], 3. preetip489980@gmail.com[3], 4. omshiprasingh8533@gmail.com 5. infokrishnajee1997@gmail.com

1. LECTURER; (DEPARTMENT OF PHARMACY), CARE COLLEGE, BAHARABAD, HARIDWAR, UTTARAKHAND, INDIA.

2. ASSISTANT PROFESSOR; (DEPARTMENT OF PHARMACEUTICS), CARE COLLEGE, BAHADRABAD, HARIDWAR, UTTARAKHAND, INDIA.

3. ASSISTANT PROFESSOR; (DEPARTMENT OF PHARMACOLOGY), BABU BANARSI DAS UNIVERSITY, LUCKNOW, UTTAR PRADESH, INDIA.

4. Q.A. EXECUTIVE; (QUALITY ASSURANCE), JUBILANT GENERICS LIMITED, BHAGWANPUR, ROORKEE, UTTARAKHAND, INDIA.

5. LECTURER; (DEPARTMENT OF PHARMACY), CARE COLLEGE, BAHARABAD, HARIDWAR, UTTARAKHAND, INDIA.

ABSTRACT

The United Nation Agency or WHO has promulgated the recent multiregional Monkey-Pox outbreak a global major health threat. The zoonotic virus that causes monkeypox is found in West and Central Africa. It is a member of the family Poxviridae, which is often made up of large, complicated, linear, enclosed viruses with double strands of DNA. Monkey pox frequently manifests as fever, myalgia, tiredness, lymphadenopathy, and a strong headache. The skin lesions usually appear one to three days after the fever starts. In intimate touch with an infected individual or animal, monkeypox is spread.There isn't a specific drug for monkey pox at the moment; instead, antiviral medications that have been approved for smallpox infections, such as tecovirimat, cidofovir, and brincidofovir, are the only accessible treatments. Vaccinia Immune The U.S. Food and Drug Administration has authorized intravenous globulin for treating issues related to vaccinations.. DNA Ligase is used to diagnose it. The U.S. Food and Drug Administration presently have licenses for two vaccinations. The WHO advises against using first-generation smallpox vaccines that are kept in national stocks in certain nations because they do not adhere to the most recent safety and production requirements. In 1970, the first reports of human monkey pox were made. Numerous epidemics have since been brought on by it, mostly in central and west Africa. IN In this review we will discuss about an updated summary of our current understanding of the pathophysiology, symptoms, treatment patterns, prevention, transmission, and circulation of monkey pox in human communities. Finally, conclusions and future prospects are reviewed.

KEYWORDS

Cytomegalovirus (CMV), Cidofovir, Kinase Thymidylate, Smallpox Vaccine, Monkey Pox.

INTRODUCTION

The emergence of a new upsurge of the monkey-pox virus has elevated concerns between health officials about supposing that it could pose incipient menace to society, especially as the world continues to deal with the COVID-19 pandemic. [1, 2] The orthopoxvirus family includes the monkeypox virus. Various studies on pox virus shows that the have double stranded DNA structure which is very large in size with 130 to 360 kbp genomic size. The replication and survival rate of the virus in the host body is very low due large genomic size. The virulent genes which are present around the orthopoxviruses work as modulator for the host immune system. [3] The MPVX replicates when it enters in the nasopharyngeal and oropharyngeal mucosa of the human host cells. The viral infection spread all over the body by the lymph nodes. [4] The outbreak of MPVX mainly occur in regions of core and the dark continent since 1970s. Primary outbreak of monkey pox outward Africa is seen within US in the year 2003. [5] The small scale outbreak of MPVX is controlled by giving antivirals and vaccinia immune-globulin because according to (CDC) Centres for Disease Control there are nonspecific medicines accessible for the treatment of monkeypox. [6,7] Globally, these sudden, unheard-of, and abnormally high-frequency transmission epidemics have drawn media, political, and scientific interest. In order to increase anticipation and early conciliation & to support the progress of particular medications, it is imperative that pathophysiological aspects, routes of transmission, clinical features, and preliminary diagnosis be investigated. Understanding these factors can lead to more effective strategies in managing and mitigating the impact of these outbreaks. [8]

TRANSMISION & CIRCULATION OF MPOX IN HUMAN POPULATIONS

In the Équateur Province of the Democratic Republic of the Congo, MPOX was first identified by humans in Basankusu in 1970. [9] The country formerly known as Zaire is now called the Democratic Republic of the Congo. [10] The case fatality rate (CFR) for previous outbreaks in May 2022 ranged from 3% to 6%, whereas the CFR for the 2022 outbreak stayed around 1%. Until 2022, there had been no record of Mpox transfers from person to person outbreak of Mpox throughout Europe. [11] Mpox is generally connected with tropical rainforests and their environment. The trend was broken in 2005 when 49 cases of the illness were reported in South Sudan (formerly part of Sudan) but no one was killed. The virus most likely originated from the Democratic Republic of the Congo, not Sudan. [12] Mpox cases in central and western Africa increased significantly between 2011 and 2014, especially in the Democratic Republic of the Congo, where 2000 cases a year were reported. Estimates of the number of Mpox cases throughout time are frequently greatly exaggerated due to insufficient or unconfirmed data. Despite this, it has been suggested that the number of recorded cases of Mpox increased in 2018 and that the disease's geographic range expanded. This trend highlights the ongoing need for reliable data collection to accurately understand and address the impact of Mpox in various regions. [10]

Outbreak in the United States (2003)

A baby became ill after being bitten by a prairie dog purchased at a swap meet near Milwaukee, Wisconsin, in May 2003. [13] There had been 71 Mpox cases documented overall by the end of 2003. All cases were linked to the importation of Gambian pouched rats from Accra, Ghana, by an exotic animal distributor in Texas in April 2003. This outbreak did not result in any recorded fatalities. When a patient has Mpox, they typically have prodromal symptoms like fever, chills, headaches, muscle aches, drenching sweats, and fever. About one-third of the cases were infected people with ineffective coughs. [14]

Outbreak in Nigeria (2017–2019)

There have been reports of an Mpox outbreak in southern and southeast Nigeria. The following states were affected by the virus: The Federal Capital Territory, Lagos, Nasarawa, Oyo, Plateau, Rivers, Abia, Bayelsa, Benue, Cross River, Delta, Edo, Ekiti, Enugu, Imo, and Akwa Ibom. [15,16] Ten human cases of Mpox were reported between

1971 and 1978, according to data from the Nigeria Centre for Disease Control. [17] In 2017, the first documented human case of Mpox was reported in the state of Bayelsa. The recent outbreak presents a shift from previous reports of the West African clade (a set of biological entities, including species, that encompass all descendants of a single common ancestor). Unlike earlier instances, this outbreak is primarily affecting male young people, with limited transmission to others. Additionally, the Niger Delta University Teaching Hospital has reported cases of young adults co-infected with HIV, syphilis, and vaginal ulcers, highlighting the complex health challenges in the region. [18]

Outbreak in the United Kingdom (2018)

The first Mpox case was reported in the UK in September 2018. It is believed that the person, a Nigerian national, contracted Mpox in Nigeria before coming to the UK. [19] As part of the broader Mpox epidemic brought on by the West African lineage of the Mpox virus, a significant outbreak of Mpox was documented in the UK in 2022. As of October 3, 2022, there were 3504 confirmed cases of Mpox, and 150 cases are most likely. [20, 21]

Outbreak in Singapore (2019)

Following confirmation that he was the nation's first Mpox case, a 38-year-old Nigerian man who had traveled from his home country to Singapore was admitted to the National Centre for Infectious Diseases in Singapore, it was revealed on May 8, 2019. 22 people were consequently put under quarantine. The case may have been connected to an outbreak that was concurrently occurring in Nigeria. [22]

2022 Outbreak

Mpox was first identified in May 2022 during an outbreak originating in the United Kingdom. [14] While some evidence suggests that the disease was spreading in Europe months earlier, the first confirmed case was reported on May 6, 2022, in a traveller from Nigeria, where the disease is endemic. [23] Since May 18, 2018, a gradually increasing number of cases have been recorded from a growing number of countries and locations, primarily from Asia, Africa, Australia, and North and South America. There have been 1,290 verified new cases as of June 9. [24,25]

PATHOPHYSIOLOGY

The appearance of the disease may depend on the class and entry place of the monkeypox virus. This virus can cause a cytopathic and productive infection by infecting keratinocytes, fibroblasts, and endothelial cells in the skin, as well as airway epithelial cells in the respiratory system. [26,27] Additionally, antigen-presenting cells such as dendritic cells, macrophages, and (in the skin) Langerhans cells can survive long enough to deliver antigens to draining lymph nodes when an infection is aborted. Viral replication, gene expression, and virion assembly in the host cell's cytoplasm result in mature virions with a single lipid membrane. This is followed by the release of extracellular viruses with an additional envelope. [28]

The monkeypox virus spreads from the initial infection site to draining lymph nodes through antigen-presenting cell migration and direct viral access to lymphatic channels. Additionally, other large organs such as the liver and spleen are susceptible to the monkeypox virus, which can replicate in those organs and lead to a second significant viral wave. After initial replication in the lymph nodes, which leads to a low-grade primary viremia, this could then allow the virus to travel further to distant organs such as the lung, kidneys, digestive system, and skin. In non-human primate models of the respiratory-acquired clade 1 monkeypox virus, researchers have observed the progression of the infection and its impact on various organ systems. This highlights the importance of understanding the pathways and mechanisms through which the virus spreads within the host during the incubation phase (up to post-challenge day 4). Before moving on to the tonsils, spleen, liver, colon, and other lymphoid organs, as well as the regional lymph nodes, where it intensifies until day six, the virus replicates in the respiratory epithelium. The virus is eventually detected in the blood on day 8, and its concentration continues to increase until day 10, at which point it also results

in widespread sores on the skin and mucous membranes. Mouth and throat ulcers release large quantities of virus particles, which are dispersed by large respiratory droplets.

After infections with clade 2 monkeypox virus, studies on subcutaneous injection models in primates demonstrate mild localized disease, with viral replication confined to the skin and lymphatic system. The digestive, respiratory, and following a clade 1 monkeypox virus skin inoculation, genitourinary tracts may be impacted. [29-31] Variolation, or immunization with the variola or vaccinia viruses, results in localized lesions near the point of entry. This is currently the only available data on human skin inoculation. [32] During the 2022 outbreak, most individuals who contracted the monkeypox virus through sexual intercourse displayed local oral and anogenital lesions. However, some also exhibited a few distal lesions on their faces, limbs, and trunks. [33-36]

When skin lesions are in the vesicular stage, histopathological examination can show dermal oedema, significant spongiosis, ballooning keratinocyte degeneration, as well as severe inflammation. [37] Few viable keratinocytes are present at the pustule stage, which is dominated by inflammatory cells and apoptotic keratinocyte debris. Viable keratinocytes may display cytopathic damage, including eosinophilic inclusion bodies, conspicuous nucleoli, and so-called ground glass chromatin, or they may be multinucleated. According to immunochemistry, the virus is present in the cytoplasm of every keratinocyte in the afflicted epidermis (but not in the unaffected one). T lymphocytes, including CD4+ and CD8+ components, make up the majority of the lymphocytic infiltration. [38]

In individuals who recover from monkeypox virus infection, humoral and cellular immune responses are generated that prevent viral replication and provide long-term immunity. [39-44] IgM and IgG antibodies that are specific to orthopoxvirus target various antigen sites and maintain long-term persistence through residual IgG-memory B cells. This comprises the humoral immune response following a spontaneous monkeypox infection or vaccination with the vaccinia virus [42-43] which prevents re-infection or the onset of severe illness. [39] After receiving a vaccine against the vaccinia virus, some memory B cells can survive for decades, but after 20 years, only 50% of persons have protective levels of neutralizing antibodies. It is likely that cross-protective immunity against monkeypox will also eventually wane. The cellular immune response is typified by a rapid rise in activated effector CD4+ and CD8+ T cells after a spontaneous monkeypox infection or vaccinia virus vaccination. This is followed by a steady drop that typically recovers to normal 12–20 days after the onset of symptoms. [40-44]

B-cell responses are critical for protection in non-human primates that have received prior vaccinations, while CD4+ or the ability of CD8+ T cells to prevent illness is marginal. [43]
It is worrying nonetheless, as CD4 reduction prior to vaccination boosted illness severity and inhibited the production of such protective B-cell responses and antibodies. [45]

SYMPTOMS

The signs and symptoms of monkeypox are less severe than those of smallpox. Patients typically experience headache, fever, enlarged lymph nodes, and fatigue when they have an infection. Fever and vesicular and pustular rash, which are identical to smallpox, appear one to three days after infection. Long-term face-to-face contact with infected individuals and respiratory droplets are the main ways that the MPVX is spread from person to person. The virus can also be transferred via direct contact with bodily fluids from an infected person or by coming into contact with contaminated clothing, bedding, or linens. After coming into contact with prairie dogs or Gambia rats, doctors should also keep an eye out for signs of monkeypox, such as a high fever, cough, headache, and enlarged lymph nodes that remain for three days. The state or municipal health agencies are required to report cases of these ailments in both humans and animals. [46-47]

TREATMENT PATTERNS

For MPX infection, there is currently no clinically established remedy. Symptom management is the treatment, as it is for most viral infections. But there are things that can be done to assist prevent an outbreak. It is necessary to keep the septic person apart, cover wounds and lesions, and wear a mask most of the time until all lesion crusts fall off and

a new layer of skin forms. In extreme situations, drugs that have shown effectiveness against orthopoxviruses in animal studies, along with significant adverse reactions following vaccination, can be assessed for experimental use. Approved treatments for smallpox include vaccination immunoglobulin, tecovirimat, and brincidofovir. [48]
Despite the lack of viable therapies for monkeypox, studies have shown that the smallpox vaccine has an 85% success rate in avoiding the disease. Furthermore, certain antiviral drugs may potentially be helpful in treating infections caused by monkeypox. [49]

SMALLPOX VACCINE (ACAM2000)

ACAM2000 can provide 85% cross-protective resistance, and the US CDC has authorized its usage in emergencies in opposition to monkeypox. [50] In the case that a high-risk monkeypox exposure occurs during pregnancy, ACAM2000 mandates that patients be informed about the abnormal risk of fetal vaccinia. Fetal vaccinia can result in premature delivery, stillbirth, neonatal death, and perhaps negative mother reactions. [51] The third-generation MVABN (Modified Vaccinia Ankara-Bavarian Nordic) smallpox vaccine has been approved for use in the USA, Canada, and the EU. This vaccine may be safer because it contains a virus that cannot reproduce and has not been shown to cause any issues during pregnancy. [52]

TECOVIRIMAT (ST-246, TPOXX)

The antiviral drug tecovirimat has received FDA approval to treat smallpox in both children and adults [53]. People with severe sickness, those at risk of contracting it, and those with lesions in their mouth, eyes, or anogenital area that may be indicative of the condition are all recommended to have antiviral medication. Tecovirimat appears to be well tolerated and may shorten the duration of an infection and lower viral particle shedding, despite the lack of clinical data at this time. To evaluate how well tecovirimat treats Mpox, a clinical investigation called STOMP is underway. [54]

For pregnant or nursing women who have contracted the Mpox virus, the Centres for Disease Control and Prevention (CDC) advise using the drug tecovirimat. Despite this, animal research is the only source of knowledge about tecovirimat's effects on the fetus. [55]

Many children with Mpox who experience severe symptoms, such as encephalitis, confluent lesions, or airway obstruction, may require treatment with tecovirimat. Additionally, tecovirimat may be necessary for patients with complications like cellulitis, abscesses, ocular lesions, pneumonia, or sepsis, as well as for those with lesions in anatomical areas that could lead to strictures or scarring, including infections of the eyes, face, or genitals. Antiviral medications should be considered for children under eight, those with compromised immune systems, and those suffering from skin conditions like eczema. [56]

Approximately 360 volunteers underwent safety testing as part of the approval process to determine whether tecovirimat has any adverse effects. The results showed that the adverse impact profile was comparable to that of a placebo. [57] The most commonly reported side effects are headaches, nausea, and abdominal pain. [58]

CIDOFOVIR

Cidofovir (brand name Vistide) drug has antiviral properties that prevents the activity of DNA from viruses. Preclinical and in vitro studies have demonstrated its effectiveness against poxviruses. The FDA has approved this medication for the management of AIDS patients' cytomegalovirus (CMV) retinitis. However, it is still uncertain how effective cidofovir is in treating human monkeypox. [59-60]

In order to decrease OPV, including monkeypox CDC has a more advanced access protocol that allows the use of stored cidofovir during an outbreak. Cidofovir could be administered when a patient has a serious case of monkeypox, while it is unclear if this will be beneficial. Cidofovir may not be as safe as Brincidofovir because it can result in major kidney harm or additional adverse consequences. [61]

The CDC is currently developing an Expanded Access Investigational New Drugs program to make the medications available for use in treating monkeypox. They can use CMX-001, an altered version of cidofovir that, according to intravenous vaccination immune globulin VIGIV, exhibits antiviral efficacy against OPV species but does not have the nephrotoxicity linked to cidofovir.

A hyper-immune globulin level has received FDA approval to treat vaccinia-related side effects. With the exception of isolated keratitis, this covers diseases like dermatitis vaccinetum, growing vaccinia, severe extended vaccinia, vaccinia ailments in people with diseases of the skin, and inappropriate ailments brought on by VACV.

.

OPV epidemics such as monkeypox can be treated with VIGIV thanks to the CDC's enhanced access procedure. VIGIV is a promising strategy, but human testing for smallpox and monkeypox has not been done, and no one knows how it prevents these diseases. However, in extreme situations, physicians would consider using them to treat monkeypox. [62-64]

TEMBEXA or BRINCIDOFOVIR (CMX001)

Cidofovir is a drug that can be taken orally as brincidofovir. Compared to cidofovir, brincidofovir might have a superior safety record. It should be mentioned that, in contrast to using cidofovir to treat cytomegalovirus infections, brincidofovir has not been linked to any significant renal impairment or other adverse effects. Beginning in June 2021, the U.S.FDA authorized the use of brincidofovir to treat smallpox. [65] Its usefulness Mpox infection treatment has only been reported in a few studies. Brindidofovir has indicated efficacy against orthopoxvirus infections in animal investigations. [66-68]

Three of the patients with Mpox who received 200 mg of oral brincidofovir once a week, however, were observed to have increased liver enzyme readings; as a result, the treatment was discontinued. Despite the need to develop methods for administering these drugs to treat sickness in endemic areas, natural items and their extraits may be an encouraging source for future antiviral medications. [69-72]

In 2019, The Food and Drug Administration (FDA) authorized an additional vaccination based on
the Ankara strain, a vaccinia virus strain that has been adapted and mitigated, to be used as a preventative measure against Mpox. There are two doses of this vaccine, which is still not readily accessible. Smallpox and Mpox the formulations based on the vaccinia virus are used to create vaccines because of the mutual protection offered by the antiviral Orthopoxvirus reaction. [73-75]

RELEVANT TARGETED THERAPY

According to a prior study, the Mpox genome and the smallpox genome share 96.3% of their DNA, which encodes a number of vital proteins and enzymes necessary for their existence [76]. Therefore, one of the possible treatment approaches could be the use of a pharmacological molecule to inhibit such a wide variety of enzymes and proteins.

KINASE THYMIDYLATE

As previously reported, thymidylate kinase and thymidine diphosphate have been found to form complexes. This enzyme is an intriguing new goal because there are currently no medications that target it. Research indicates those A48R are essential for the conversion of 50 halogenated deoxyuridine monophosphate to its diphosphate and thymidine monophosphate to its diphosphate.

Because of its significant fundamental variations from the conceptually comparable human counterpart, The human thymidylate kinase active site may be a promising focus on for thymidine analogue advancement, with no regard for stopping the functionality of the analogous human.[77-78]

LIGASE FOR DNA

One crucial enzyme needed for virus replication is DNA ligase. Antiviral medication resistance has been linked to a modifications at its N-terminus. It is a useful target for drug discovery since the where resistance-causing modifications are located suggests that the medication's functioning site is there. [79]

PROTEIN TRIMER COMPLEX or D13L

Particularly significant in the morphological development of the viral particle is D13L, a vital capsid protein that forms a protein trimer complex and adds to the rigidity of the virus particle membrane. Rifampin and the D13L protein are strongly correlated because it has been demonstrated that the vaccinia virus has an affinity for it. Rifampin's has been shown that the capacity to attach to the D13L trimer complex block orthomyxovirus assembling; this impact is separate from its antibacterial activity. [78-81]

MAJOR ENVELOPE PROTEIN, or F13L

Major Envelope Protein target the F13L gene to treat poxvirus, the sole licensed medication is tecovirimat (formerly known as ST-256). In addition to being a key envelope protein, amino acids with palmitoylated membranes, which is essential in both the growth of extracellular envelope viruses (EEVs) as well as the virus's ability to enter cells. [82]

CYSTEINE PROTEINASE, or I7L

The cysteine is I7L core protein enzyme that degrades those main amino acids with structures and membranes of bacteria and virus strains. Protein enzymes are perfect targets for treatment since they cleave precursor polyproteins, which is how viruses replicate. It has been demonstrated that inhibitions of the enzyme for various other viruses, including HIV, also function against other viral proteases. Proteases of the orthomyxovirus are therefore additionally appealing targets for stopping the virus's procreation. TTP-6171 was discovered to be an I7L the enzyme inhibitor in earlier research. There is also an assumption that resistance-drugs I7L could be caused by alterations in the portion of the genome I7L. [83-84]

PREVENTION

The main methods of preventing Mpox include increasing people's knowledge of the danger signs and teaching them regarding the actions they may actions they can take to lessen their virus exposure. Researchers tends to examining if and how much immunization would be successful in treating and preventing Mpox in numerous nations worldwide.

Consequently, some nations have vaccinated or are growing programs to vaccinate those who might be in danger, including healthcare professionals, fast reaction teams, and laboratory staff. [85]

The chance of Mpox transmitting from person to person must be decreased in order to prevent the disease. Detecting new cases as quickly as feasible and conducting surveillance are critical to containing an outbreak. The primary risk factor for acquiring the human mpox virus is intimate contact with an infected person. It's important for individuals to recognize the symptoms and indicators and to seek treatment advice if they have any suspicions exposure. Public health measures, such as contact tracing and vaccination, can also play a vital role in controlling the spread of the virus. Household members and healthcare personnel are more susceptible to infection. Therefore, it is advised that medical personnel who treat patients or handle Mpox specimens adhere to accepted infection control practices. Whenever feasible, caregivers for the patient should be chosen from among those who have received a smallpox vaccination. [86]

Detecting new cases as soon as possible and conducting surveillance are critical to containing an outbreak. The primary risk factor for acquiring the human mpox virus is intimate contact with an infected person. Prompt identification of cases and monitoring potential exposures can help minimize transmission and protect public health. [87] COVID-19 taught us that any community-based effort to stop the spread of any viral epidemics would need to include early diagnosis, open data sharing, and quarantine for those who are affected. [88] To enhance sickness response and prevent prejudice, stigmatization must be reduced or avoided. In the group of LGBTQ+ people the general people in particular, hostile teaching efforts about the dissemination and spread will be beneficial lessen stigma as well as a result, the unwillingness to look for care. Education plays a crucial role in fostering understanding and compassion, ultimately leading to a more inclusive approach to health care and support. [89]

Reducing touch with the lesions is an important preventive measure because it appears that close, prolonged contact is the primary method of transmission. Sharing bedding, towels, and clothes must be avoided. Additionally, maintaining good hygiene and keeping personal items separate can further help prevent the spread of infections. [90-91]

PREVENTIVE VACCINATION AGAINST EXPOSURE

The Advisory Committee on Immunization Practices (ACIP) confirms pre-exposure prophylaxis using the modified vaccinia Ankara (MVA) vaccine for everyone who are at risk of occupational exposure to Mpox disease. This includes clinical laboratory staff, researchers engaged in orthopoxvirus traits checking, and nominate response team members who are also at threat of potential hazards. Professionals are even debating the application of the modified vaccinia Ankara vaccine as a pre-exposure preventive for individuals at elevated danger. These people might be those eligible for vaccinations whenever we have a sufficient supply of MVA vaccines. [92-94]

RISK ASSESSMENT POST EXPOSURE

After coming into contact with a monkeypox sufferer, people should keep a cautious eye out for symptoms for at least 21 days. A person can return to their regular activities if they are asymptomatic; if they become ill, they should isolate themselves and get more medical help from the health department or their primary care physician. Three types of exposure risk are listed below-

(A) Revelation to threatening

Patients who have -

(i) A person is considered to be at unsafe of uncovering if they come in touch with a diseased person's dermis, mucosa, skin blemishes, and/or bodily liquids. This can occur through sexual contact, touch with a contaminated patient's saliva in an uninfected person's mouth or eye, or contact with contaminated materials like clothing, according to the CDC.

(ii) Not wearing the proper N95 and eye protection increases the threat of aerosolizing from mouth or cutaneous blemishes, getting within six feet of an infectious patient when performing series of steps like dental work or shaking dirty, infected clothing.

(B) Exposure to Intermediate Risk

A person who is not infected and is within six feet of someone who has monkeypox and has not worn a mask for three hours or more is deemed to be at intermediate risk. At the very least, they ought to be wearing medical masks. Whenever a person with no infection wearing gloves alone and not a gown arrives into touch with body fluids, skin blemishes or unclean clothing from an infected patient, that is another example of intermediate degree exposure.

(C) Minimal Risk Exposure

A non-infected person is deemed low-risk by the CDC if they -

(i) Upon approaching the patient's space, take all necessary safety measures.; b) No matter how long you are exposed, never wear eye protection; and c) Allowing fewer than three hours devoid of wearing a mask in no more than six feet of a patient with an infection. [95]

Restrict the commerce in animals is another crucial step in preventing Mpox, and it can also help lessen the disease. Legislation restricting the importation of rodents and non-human primates has been implemented in a few nations worldwide. By enforcing such regulations, countries can reduce circulation of illnesses risk and safeguard both human and animal health. Additionally, raising public perception about the dangers of pet trade and protecting biodiversity is crucial further support these efforts. Captive animals suspected of having Mpox should be immediately isolated and quarantined from other animals. Additionally, any animals that could have been contact with diseased animals should be restricted as well, handled via standard care, and detected for signs of Mpox to at least 30 days after the interaction. [96]

CONCLUSION AND FUTURE PROSPECTIVE

The Mpox outbreak in 2022 marks a shift from a regional to a worldwide problem. With the COVID-19 pandemic, monkeypox outbreaks are expected to increase, requiring proactive efforts from all stakeholders to reduce public health risks, especially among impaired groups. [97]

APOBEC3 mutations may diminish the pathogenicity and symptoms of MPXV infection in HIV-positive people, while increasing the virus's potential to spread.[98] The rise of Mpox cases in non-endemic locations has caused global worry, straining medical budgets and perpetuating racial prejudices. MPXV infections were formerly isolated to Africa, but recent outbreaks in non-endemic locations have aroused global worries and put pressure on healthcare costs. To prevent the spread of measles, cheap vaccines should be made available to high-prevalence regions and targeted groups, particularly those with HIV. [99]

Edghill-Smith et al. [100] found that MPXV-infected macaques with HIV had impaired vaccinia-specific IgM to IgG switching. HIV-1 infection targets CD4+ cells, making immunization techniques that circumvent them crucial. FDA-approved medications Brincidofovir and Tecovirimat, previously approved for smallpox treatment, have shown efficacy against MPXV infection in animal models. Although there is less proof on their usefulness for Mpox patients, these two medications were approved for emergency use because of their antiviral efficacy in animal models. [101]

ACKNOWLEDGEMENT

I would like to express my sincere gratitude to all those who supported and contributed to the successful completion of this review article. First and foremost, I am deeply thankful to Mr. Rajkumar Sharma MD of CARE College & Mrs. Preetshikha Sharma Director of CARE College, Haridwar and Mrs. Shubhangini Sharma Additional Director of CARE College for their unwavering support, invaluable guidance, and encouragement throughout the preparation of this review article.

I am especially grateful to Mr. Krishna Jee for his continuous mentorship, constructive feedback, and insightful suggestions, which were essential in shaping the direction of this article. Their encouragement has been a major driving force behind this work. Your meticulous attention to detail, constructive feedback, and thought-provoking suggestions have helped me to refine the content and ensure that this review is of the highest quality. I am truly fortunate to have the opportunity to work under your mentorship.

I also want to extend my heartfelt thanks to my colleagues and fellow authors who offered their time and knowledge, helping me gather relevant information and providing useful resources that played a key role in completing this article. Your contributions to the methodology and critical evaluation of the studies cited in this article have been invaluable. I greatly appreciate the time and effort they have devoted to reviewing drafts and offering feedback that greatly improved the quality of the final version.

Finally, I would like to express my deepest gratitude to my family and friends for their constant support, patience and understanding. Their encouragement has been invaluable, and their belief in me provided the motivation to push through challenges.

This work would not have been possible without the contributions of all these individuals, and I am truly grateful for their support.

REFERENCE

1. McQuiston, J. H. (2024). US preparedness and response to increasing clade I mpox cases in the Democratic Republic of the Congo—United States, 2024. MMWR. Morbidity and Mortality Weekly Report, 73.

2. Chakraborty, C., Bhattacharya, M., Nandi, S. S., Mohapatra, R. K., Dhama, K., & Agoramoorthy, G. (2022). Appearance and re-appearance of zoonotic disease during the pandemic period: long-term monitoring and analysis of zoonosis is crucial to confirm the animal origin of SARS-CoV-2 and monkeypox virus. Veterinary Quarterly, 42(1), 119-124.

3. Okyay, R. A., Bayrak, E., Kaya, E., Şahin, A. R., Koçyiğit, B. F., Taşdoğan, A. M., ... & Sümbül, H. E. (2022). Another epidemic in the shadow of Covid 19 pandemic: a review of monkeypox. proteins, 7(10), 10-14744.

4. Okyay, R. A., Bayrak, E., Kaya, E., Şahin, A. R., Koçyiğit, B. F., Taşdoğan, A. M., ... & Sümbül, H. E. (2022). Another epidemic in the shadow of Covid 19 pandemic: a review of monkeypox. proteins, 7(10), 10-14744.

5. Sale, T. A., Melski, J. W., & Stratman, E. J. (2006). Monkeypox: an epidemiologic and clinical comparison of African and US disease. Journal of the American Academy of Dermatology, 55(3), 478-481.

6. Huang, Y. A., Howard-Jones, A. R., Durrani, S., Wang, Z., & Williams, P. C. (2022). Monkeypox: A clinical update for paediatricians. Journal of Paediatrics and Child Health, 58(9), 1532-1538.

7. Rizk, J. G., Lippi, G., Henry, B. M., Forthal, D. N., & Rizk, Y. (2022). Prevention and treatment of monkeypox. Drugs, 82(9), 957-963.

8. Cho CT, Wenner HA. Monkeypox virus. Bacteriol Rev (1973) 37(1):1–18. doi:10.1128/br.37.1.1-18.1973

9. Marennikova, S. S., Šeluhina, E. M., Mal'Ceva, N. N., Čimiškjan, K. L., & Macevič, G. R. (1972). Isolation and properties of the causal agent of a new variola-like disease (monkeypox) in man. Bulletin of the World Health Organization, 46(5), 599.

10. Kozlov, M. (2022). Monkeypox goes global: why scientists are on alert.

11. Fuller, T., Thomassen, H. A., Mulembakani, P. M., Johnston, S. C., Lloyd-Smith, J. O., Kisalu, N. K., ... & Rimoin, A. W. (2011). Using remote sensing to map the risk of human monkeypox virus in the Congo Basin. EcoHealth, 8, 14-25.

12. Bunge, E. M., Hoet, B., Chen, L., Lienert, F., Weidenthaler, H., Baer, L. R., & Steffen, R. (2022). The changing epidemiology of human monkeypox—A potential threat? A systematic review. PLoS neglected tropical diseases, 16(2), e0010141.

13. Reynolds, M. G., Davidson, W. B., Curns, A. T., Conover, C. S., Huhn, G., Davis, J. P., ... & Damon, I. K. (2007). Spectrum of infection and risk factors for human monkeypox, United States, 2003. Emerging infectious diseases, 13(9), 1332.

14. Minhaj, F. S., Ogale, Y. P., Whitehill, F., Schultz, J., Foote, M., Davidson, W., ... & Wong, M. (2022). Monkeypox outbreak—Nine states, May 2022: Weekly/June 10, 2022/71 (23); 764–769.

15. Kabuga, A. I., & El Zowalaty, M. E. (2019). A review of the monkeypox virus and a recent outbreak of skin rash disease in Nigeria. Journal of medical virology, 91(4), 533-540.

16. Yinka-Ogunleye, A., Aruna, O., Ogoina, D., Aworabhi, N., Eteng, W., Badaru, S., ... & Ihekweazu, C. (2018). Reemergence of human monkeypox in Nigeria, 2017. Emerging infectious diseases, 24(6), 1149.

17. Okareh, O. T., & Morakinyo, O. M. (2018). Monkeypox in Nigeria: A case report of re-emerged disease outbreak. J. Microbiol. Exp, 6(2), 89-91.

18. Silenou, B. C., Tom-Aba, D., Adeoye, O., Arinze, C. C., Oyiri, F., Suleman, A. K., ... & Krause, G. (2020). Use of surveillance outbreak response management and analysis system for human monkeypox outbreak, Nigeria, 2017–2019. Emerging infectious diseases, 26(2), 345.

19. Vivancos, R., Anderson, C., Blomquist, P., Balasegaram, S., Bell, A., Bishop, L., ... & Hopkins, S. (2022). Community transmission of monkeypox in the United Kingdom, April to May 2022. Eurosurveillance, 27(22), 2200422.

20. UK, G. (2022). Artificial Intelligence and Intellectual Property: copyright and patents (2021a).[online] https://www. gov. uk/government/consultations/artificial-intelligence-and-ip-copyright-and-patents/artificial-intelligence-and-intellectual-property-copyright-and-patents.

21. Ward, T., Christie, R., Paton, R. S., Cumming, F., & Overton, C. E. (2022). Transmission dynamics of monkeypox in the United Kingdom: contact tracing study. bmj, 379.

22. Yong, S. E. F., Ng, O. T., Ho, Z. J. M., Mak, T. M., Marimuthu, K., Vasoo, S., ... & Leo, Y. S. (2020). Imported Monkeypox, Singapore. Emerging infectious diseases, 26(8), 1826.

23. Velavan, T. P., & Meyer, C. G. (2022). Monkeypox 2022 outbreak: an update. Trop Med Int Health, 27(7), 604-605.

24. Miura, F., van Ewijk, C. E., Backer, J. A., Xiridou, M., Franz, E., de Coul, E. O., ... & Wallinga, J. (2022). Estimated incubation period for monkeypox cases confirmed in the Netherlands, May 2022. Eurosurveillance, 27(24), 2200448.

25. Simões, P., & Bhagani, S. (2022). A viewpoint: The 2022 monkeypox outbreak. Journal of Virus Eradication, 8(2).

26. Liu, L., Xu, Z., Fuhlbrigge, R. C., Pena-Cruz, V., Lieberman, J., & Kupper, T. S. (2005). Vaccinia virus induces strong immunoregulatory cytokine production in healthy human epidermal keratinocytes: a novel strategy for immune evasion. Journal of virology, 79(12), 7363-7370.

27. MacLeod, D. T., Nakatsuji, T., Wang, Z., Di Nardo, A., & Gallo, R. L. (2015). Vaccinia virus binds to the scavenger receptor MARCO on the surface of keratinocytes. Journal of Investigative Dermatology, 135(1), 142-150.

28. Realegeno, S., Puschnik, A. S., Kumar, A., Goldsmith, C., Burgado, J., Sambhara, S., ... & Satheshkumar, P. S. (2017). Monkeypox virus host factor screen using haploid cells identifies essential role of GARP complex in extracellular virus formation. Journal of virology, 91(11), 10-1128.

29. Zaucha, G. M., Jahrling, P. B., Geisbert, T. W., Swearengen, J. R., & Hensley, L. (2001). The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Laboratory investigation, 81(12), 1581-1600.

30. Tree, J. A., Hall, G., Pearson, G., Rayner, E., Graham, V. A., Steeds, K., ... & Vipond, J. (2015). Sequence of pathogenic events in cynomolgus macaques infected with aerosolized monkeypox virus. Journal of virology, 89(8), 4335-4344.

31. Saijo, M., Ami, Y., Suzaki, Y., Nagata, N., Iwata, N., Hasegawa, H., ... & Morikawa, S. (2009). Virulence and pathophysiology of the Congo Basin and West African strains of monkeypox virus in non-human primates. Journal of general virology, 90(9), 2266-2271.

32. Fenner, F., Henderson, D. A., Arita, I., Ježek, Z., & Ladnyi, I. D. (1987). Smallpox and its eradication. Geneva: WHO, 210.

33. Thornhill, J. P., Barkati, S., Walmsley, S., Rockstroh, J., Antinori, A., Harrison, L. B., ... & Orkin, C. M. (2022). Monkeypox virus infection in humans across 16 countries—April–June 2022. New England Journal of Medicine, 387(8), 679-691.

34. Patel, A., Bilinska, J., Tam, J. C., Fontoura, D. D. S., Mason, C. Y., Daunt, A., ... & Nori, A. (2022). Clinical features and novel presentations of human monkeypox in a central London centre during the 2022 outbreak: descriptive case series. bmj, 378.

35. Tarín-Vicente, E. J., Alemany, A., Agud-Dios, M., Ubals, M., Suñer, C., Antón, A., ... & Mitjà, O. (2022). Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study. The Lancet, 400(10353), 661-669.

36. Català, A., Clavo-Escribano, P., Riera-Monroig, J., Martín-Ezquerra, G., Fernandez-Gonzalez, P., Revelles-Peñas, L., ... & Fuertes, I. (2022). Monkeypox outbreak in Spain: clinical and epidemiological findings in a prospective cross-sectional study of 185 cases. British Journal of Dermatology, 187(5), 765-772.

37. Bayer-Garner, I. B. (2005). Monkeypox virus: histologic, immunohistochemical and electron-microscopic findings. Journal of cutaneous pathology, 32(1), 28-34.

38. Maronese, C. A., Beretta, A., Avallone, G., Boggio, F. L., Marletta, D. A., Murgia, G., ... & Marzano, A. V. (2022). Clinical, dermoscopic and histopathological findings in localized human monkeypox: a case from northern Italy. The British journal of dermatology, 187(5), 822.

39. Karem, K. L., Reynolds, M., Hughes, C., Braden, Z., Nigam, P., Crotty, S., ... & Damon, I. K. (2007). Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection. Clinical and Vaccine Immunology, 14(10), 1318-1327.

40. Shao, L., Huang, D., Wei, H., Wang, R. C., Chen, C. Y., Shen, L., ... & Chen, Z. W. (2009). Expansion, reexpansion, and recall-like expansion of Vγ2Vδ2 T cells in smallpox vaccination and monkeypox virus infection. Journal of virology, 83(22), 11959-11965.

41. Zaeck, L. M., Lamers, M. M., Verstrepen, B. E., Bestebroer, T. M., Van Royen, M. E., Götz, H., ... & De Vries, R. D. (2023). Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals. Nature medicine, 29(1), 270-278.

42. Agrati, C., Cossarizza, A., Mazzotta, V., Grassi, G., Casetti, R., De Biasi, S., ... & Antinori, A. (2023). Immunological signature in human cases of monkeypox infection in 2022 outbreak: an observational study. The Lancet Infectious Diseases, 23(3), 320-330.

43. Edghill-Smith, Y., Golding, H., Manischewitz, J., King, L. R., Scott, D., Bray, M., ... & Franchini, G. (2005). Smallpox vaccine–induced antibodies are necessary and sufficient for protection against monkeypox virus. Nature medicine, 11(7), 740-747.

44. Hammarlund, E., Dasgupta, A., Pinilla, C., Norori, P., Früh, K., & Slifka, M. K. (2008). Monkeypox virus evades antiviral CD4+ and CD8+ T cell responses by suppressing cognate T cell activation. Proceedings of the National Academy of Sciences, 105(38), 14567-14572.

45. Smith, Y. E., Bray, M., Whitehouse, C. A., Miller, D., Mucker, E., Manischewitz, J., ... & Franchini, G. (2005). Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge. The Journal of infectious diseases, 191(3), 372-381.

46. Guarner, J., Johnson, B. J., Paddock, C. D., Shieh, W. J., Goldsmith, C. S., Reynolds, M. G., ... & Veterinary Monkeypox Virus Working Group. (2004). Monkeypox transmission and pathogenesis in prairie dogs. Emerging infectious diseases, 10(3), 426.

47. Ligon, B. L. (2004, October). Monkeypox: a review of the history and emergence in the Western hemisphere. In Seminars in pediatric infectious diseases (Vol. 15, No. 4, pp. 280-287). WB Saunders.

48. Reddy, K. (2018). Is smallpox Dead?(The story of highly contagious and most feared disease). J. Gandaki Med. College-Nepal 11 (1), I-XI. doi: 10.3126/jgmcn.v11i1.20784

49. Kmiec, D., & Kirchhoff, F. (2022). Monkeypox: a new threat?. International journal of molecular sciences, 23(14), 7866.

50. Reynolds, M. G., McCollum, A. M., Nguete, B., Shongo Lushima, R., & Petersen, B. W. (2017). Improving the care and treatment of monkeypox patients in low-resource settings: applying evidence from contemporary biomedical and smallpox biodefense research. Viruses, 9(12), 380.

51. Mbala, P. K., Huggins, J. W., Riu-Rovira, T., Ahuka, S. M., Mulembakani, P., Rimoin, A. W., ... & Muyembe, J. J. T. (2017). Maternal and fetal outcomes among pregnant women with human monkeypox infection in the Democratic Republic of Congo. The Journal of infectious diseases, 216(7), 824-828.

52. Khalil, A., Samara, A., O'Brien, P., Morris, E., Draycott, T., Lees, C., & Ladhani, S. (2022). Monkeypox vaccines in pregnancy: lessons must be learned from COVID-19. The Lancet Global Health, 10(9), e1230-e1231.

53. US Food and Drug Administration. (2018). FDA approves the first drug with an indication for treatment of smallpox. US Food and Drug Administration, 13.

54. Parker, S., Handley, L., & Buller, R. M. (2008). Therapeutic and prophylactic drugs to treat orthopoxvirus infections. Future Virology, 3(6), 595-612.

55. Lederman, E. R., Davidson, W., Groff, H. L., Smith, S. K., Warkentien, T., Li, Y., ... & Damon, I. K. (2012). Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. The Journal of infectious diseases, 206(9), 1372-1385.

56. Adler, H., Gould, S., Hine, P., Snell, L. B., Wong, W., Houlihan, C. F., ... & Hruby, D. E. (2022). Clinical features and management of human monkeypox: a retrospective observational study in the UK. The Lancet Infectious Diseases, 22(8), 1153-1162.

57. Grosenbach, D. W., Honeychurch, K., Rose, E. A., Chinsangaram, J., Frimm, A., Maiti, B., ... & Hruby, D. E. (2018). Oral tecovirimat for the treatment of smallpox. New England Journal of Medicine, 379(1), 44-53.

58. O'Laughlin, K. (2022). Clinical use of tecovirimat (Tpoxx) for treatment of monkeypox under an investigational new drug protocol—United States, May–August 2022. MMWR. Morbidity and mortality weekly report, 71.

59. Lanier, R., Trost, L., Tippin, T., Lampert, B., Robertson, A., Foster, S., ... & Painter, G. (2010). Development of CMX001 for the treatment of poxvirus infections. Viruses, 2(12), 2740.

60. Rice, A. D., Adams, M. M., Wallace, G., Burrage, A. M., Lindsey, S. F., Smith, A. J., ... & Moyer, R. W. (2011). Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. Viruses, 3(1), 47.

61. Chittick, G., Morrison, M., Brundage, T., & Nichols, W. G. (2017). Short-term clinical safety profile of brincidofovir: A favorable benefit–risk proposition in the treatment of smallpox. Antiviral research, 143, 269-277.

62. Parker, S., Handley, L., & Buller, R. M. (2008). Therapeutic and prophylactic drugs to treat orthopoxvirus infections. Future Virology, 3(6), 595-612.

63. Wittek, R. (2006). Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy. International journal of infectious diseases, 10(3), 193-201.

64. Weinstein, R. A., Nalca, A., Rimoin, A. W., Bavari, S., & Whitehouse, C. A. (2005). Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clinical infectious diseases, 41(12), 1765-1771.

65. US Food and Drug Administration. (2022). FDA approves drug to treat smallpox. Erişim tarihi, 21.

66. Parker, S., Chen, N. G., Foster, S., Hartzler, H., Hembrador, E., Hruby, D., ... & Buller, R. M. (2012). Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox–an animal model of smallpox. Antiviral research, 94(1), 44-53.

67. Hutson, C. L., Kondas, A. V., Mauldin, M. R., Doty, J. B., Grossi, I. M., Morgan, C. N., ... & Olson, V. A. (2021). Pharmacokinetics and efficacy of a potential smallpox therapeutic, brincidofovir, in a lethal monkeypox virus animal model. MSphere, 6(1), 10-1128.

68. Rice, A. D., Adams, M. M., Wallace, G., Burrage, A. M., Lindsey, S. F., Smith, A. J., ... & Moyer, R. W. (2011). Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. Viruses, 3(1), 47.

69. Sherwat, A., Brooks, J. T., Birnkrant, D., & Kim, P. (2022). Tecovirimat and the treatment of monkeypox—past, present, and future considerations. New England Journal of Medicine, 387(7), 579-581.

70. Khalid, S., Almalki, F. A., Hadda, T. B., Bader, A., Abu-Izneid, T., Berredjem, M., ... & Alqahtani, A. M. (2021). Medicinal applications of cannabinoids extracted from Cannabis sativa (L.): a new route in the fight against COVID-19?. Current pharmaceutical design, 27(13), 1564-1578.

71. Alandijany, T. A., El-Kafrawy, S. A., Al-Ghamdi, A. A., Qashqari, F. S., Faizo, A. A., Tolah, A. M., ... & Azhar, E. I. (2021, January). Lack of antibodies to SARS-CoV-2 among blood donors during COVID-19 lockdown: a study from Saudi Arabia. In Healthcare (Vol. 9, No. 1, p. 51). MDPI.

72. Vora, S., Damon, I., Fulginiti, V., Weber, S. G., Kahana, M., Stein, S. L., ... & Marcinak, J. (2008). Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clinical Infectious Diseases, 46(10), 1555-1561.

73. Stittelaar, K. J., van Amerongen, G., Kondova, I., Kuiken, T., van Lavieren, R. F., Pistoor, F. H., ... & Osterhaus, A. D. (2005). Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. Journal of virology, 79(12), 7845-7851.

74. Petersen, B. W., Damon, I. K., Pertowski, C. A., Meaney-Delman, D., Guarnizo, J. T., Beigi, R. H., ... & Willoughby, R. E. (2015). Clinical guidance for smallpox vaccine use in a postevent vaccination program. MMWR Recomm Rep, 64(RR-02), 1-26.

75. Petersen, B. W., Kabamba, J., McCollum, A. M., Lushima, R. S., Wemakoy, E. O., Tamfum, J. J. M., ... & Reynolds, M. G. (2019). Vaccinating against monkeypox in the Democratic Republic of the Congo. Antiviral research, 162, 171-177.

76. Shchelkunov, S. N., Totmenin, A. V., Babkin, I. V., Safronov, P. F., Ryazankina, O. I., Petrov, N. A., ... & Sandakhchiev, L. S. (2001). Human monkeypox and smallpox viruses: genomic comparison. FEBS letters, 509(1), 66-70.

77. Caillat, C., Topalis, D., Agrofoglio, L. A., Pochet, S., Balzarini, J., Deville-Bonne, D., & Meyer, P. (2008). Crystal structure of poxvirus thymidylate kinase: an unexpected dimerization has implications for antiviral therapy. Proceedings of the National Academy of Sciences, 105(44), 16900-16905.

78. Prichard, M. N., & Kern, E. R. (2012). Orthopoxvirus targets for the development of new antiviral agents. Antiviral research, 94(2), 111-125.

79. Deng, L., Dai, P., Ciro, A., Smee, D. F., Djaballah, H., & Shuman, S. (2007). Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virion assembly. Journal of virology, 81(24), 13392-13402.

80. Bahar, M. W., Graham, S. C., Stuart, D. I., & Grimes, J. M. (2011). Insights into the evolution of a complex virus from the crystal structure of vaccinia virus D13. Structure, 19(7), 1011-1020.

81. Garriga, D., Headey, S., Accurso, C., Gunzburg, M., Scanlon, M., & Coulibaly, F. (2018). Structural basis for the inhibition of poxvirus assembly by the antibiotic rifampicin. Proceedings of the National Academy of Sciences, 115(33), 8424-8429.

82. Moss, B. (2016, December). Membrane fusion during poxvirus entry. In Seminars in cell & developmental biology (Vol. 60, pp. 89-96). Academic Press.

83. Byrd, C. M., Bolken, T. C., Mjalli, A. M., Arimilli, M. N., Andrews, R. C., Rothlein, R., ... & Hruby, D. E. (2004). New class of orthopoxvirus antiviral drugs that block viral maturation. Journal of virology, 78(22), 12147-12156.

84. Zephyr, J., Yilmaz, N. K., & Schiffer, C. A. (2021). Viral proteases: Structure, mechanism and inhibition. In The enzymes (Vol. 50, pp. 301-333). Academic Press.

85. Tufail, A., Pullan, S., Amini, A., & Komath, D. (2022). Deep masseteric layer. British Dental Journal, 232(11), 760-760.

86. Petersen, E., Kantele, A., Koopmans, M., Asogun, D., Yinka-Ogunleye, A., Ihekweazu, C., & Zumla, A. (2019). Human monkeypox: epidemiologic and clinical characteristics, diagnosis, and prevention. Infectious Disease Clinics, 33(4), 1027-1043.

87. Velavan, T. P., & Meyer, C. G. (2022). Monkeypox 2022 outbreak: an update. Trop Med Int Health, 27(7), 604-605.

88. Chang, C. T., Thum, C. C., Lim, X. J., Chew, C. C., & Rajan, P. (2022). Monkeypox outbreak: Preventing another episode of stigmatisation. Trop Med Int Health, 27(9), 754-757.

89. Roess, A. A., Monroe, B. P., Kinzoni, E. A., Gallagher, S., Ibata, S. R., Badinga, N., ... & Reynolds, M. G. (2011). Assessing the effectiveness of a community intervention for monkeypox prevention in the Congo basin. PLoS neglected tropical diseases, 5(10), e1356.

90. World Health Organization. (2022). Multi-country monkeypox outbreak in non-endemic countries. 2022.

91. Centers for Disease Control. Potential exposure to person with confirmed human Monkeypox Infection—United States, 2021.

92. Isaacs, S. N., Shenoy, E. S., Goldfarb, I. T., & Palmore, T. N. Treatment and prevention of mpox (formerly monkeypox).

93. Petersen, E., Zumla, A., Hui, D. S., Blumberg, L., Valdoleiros, S. R., Amao, L., ... & Koopmans, M. P. G. (2022). Vaccination for monkeypox prevention in persons with high-risk sexual behaviours to control on-going outbreak of monkeypox virus clade 3. International Journal of Infectious Diseases, 122, 569-571.

94. Centers for Disease Control and Prevention. (2022). Monkeypox outbreak global map. 2022. Accessed November, 21, 2022.

95. Bunge, E. M., Hoet, B., Chen, L., Lienert, F., Weidenthaler, H., Baer, L. R., & Steffen, R. (2022). The changing epidemiology of human monkeypox—A potential threat? A systematic review. PLoS neglected tropical diseases, 16(2), e0010141.

96. Sklenovská, N., & Van Ranst, M. (2018). Emergence of monkeypox as the most important orthopoxvirus infection in humans. Frontiers in public health, 6, 383729.

97. Yang, Z. (2022). Monkeypox: A potential global threat?. Journal of medical virology, 94(9), 4034.

98. Chen, Y., Li, M., & Fan, H. (2022). The monkeypox outbreak in 2022: adaptive evolution associated with APOBEC3 may account for. Signal Transduction and Targeted Therapy, 7(1), 323.

99. Nakoune, E., & Olliaro, P. (2022). Waking up to monkeypox. Bmj, 377.

100. Smith, Y. E., Bray, M., Whitehouse, C. A., Miller, D., Mucker, E., Manischewitz, J., ... & Franchini, G. (2005). Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge. The Journal of infectious diseases, 191(3), 372-381.

101. Adler, H., Gould, S., Hine, P., Snell, L. B., Wong, W., Houlihan, C. F., ... & Hruby, D. E. (2022). Clinical features and management of human monkeypox: a retrospective observational study in the UK. The Lancet Infectious Diseases, 22(8), 1153-1162.